Skip to main content
Fig. 4 | BMC Microbiology

Fig. 4

From: Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity

Fig. 4

a) Linear discriminant analysis (LDA) effect size (LEfSe) of gut microbiota presented in the cladogram; the taxonomic levels are represented by rings. The healthy, colon-cancer, and irinotecan groups are colored in green, red, and blue, respectively; b) histogram of relative abundance of significantly noticed gut microbiota in the healthy group—(A, B, C, D, E, and F indicate Actinobacteria, Bifidobacterium, Bacteroidales S24-7, Gemmiger, Phascolarctobacterium, Desulfovibronales respectively); c) histogram of relative abundance of marked gut microbiota in Irinotecan group compared to healthy and colon cancer groups—(A, B, C, D, and E indicate Lactobacillus, Veillonella, Clostridium, Butryicicoccus, and Prevotella, respectively); d) histogram of relative abundance of gut microbiota in the colon-cancer group compared to healthy and Irinotecan groups;(A and B indicate Dialister and Enterobacteriaceae, respectively); e) predicted function of the gut microbiota in the Irinotecan, Healthy, and colon-cancer groups according to KEGG pathway hierarchy level 2 [38]. The vertical columns represent groups, and the horizontal rows depict metabolic pathways. The color coding is based on row z-scores; f) predicted function of the gut microbiota in the Irinotecan, Healthy, and colon-cancer groups according to KEGG pathway hierarchy level 3 [38]. The vertical columns represent groups, and the horizontal rows depict metabolic pathways. The color coding is based on row z-scores

Back to article page